After adjustment for Acute Physiology and Chronic Health Evaluation III score, other blood component transfusions, number of RBC transfusions, pretransfusion hemoglobin concentration, and cardiac surgery, the odds ratio for hospital mortality for patients exposed to the older three quartiles compared with the lowest quartile was 2.01 (95% confidence interval = 1.07 to 3.77).
Several survival analysis methods were used to identify relevant associations: (i) a Cox-step method [ 29], (ii) a differential analysis between the first and the fourth quartile, (iii) a classical Cox analysis.
In contrast, the OR for 28-day mortality with each quartile increase in APACHE III score was 3.28 ([0.97–11.1]), which was of borderline statistical significance (p = 0.06).
Lastly, the sample was sorted according to newborns' length at birth (Group III): those born in the lower quartile (≤47.5 centimeters (cm)) were compared with the rest of the participants.
*Parameter estimates shown are the difference when compared to patients in GDF-15 quartile 1 after adjusting for APACHE III score.
But over three years he remains a top quartile performer.
The AUC was calculated as 0.712 in quartile I, 0.754 in quartile II, 0.829 in quartile III and 0.797 in quartile IV (Table 4).
The optimal cut-off value of Cysc for diagnosing AKI increased across FT4 quartiles (quartile I and quartile II = 1.15 mg/L, quartile III =1.35 mg/L, quartile IV =1.45 mg/L).
The test for trend across quartiles used the P value from the type III analysis of effects based on the Wald χ test.
Adjusting for severity of illness measured by APACHE III score, the odds of death for patients with GDF-15 levels in the fourth quartile when compared to the first quartile was 4.26 (95% CI 2.18, 10.92, P <0.001).
After adjusting for severity of illness measured by APACHE III scores, patients with GDF-15 levels in the third and fourth quartile had significantly fewer ICU-free and ventilator-free days when compared to patients with GDF-15 levels in the first quartile (Table 4).
